Both work with your own growth-hormone axis, one has FDA-approved origins, the other is the everyday 503A option. How they actually differ.
Used for GH-axis and metabolic support under clinician supervision.
Grade A, randomized human trials behind the approved product (Egrifta).
Long-term use beyond studied indications is less characterized.
Used to support muscle, recovery, and sleep quality.
Grade C, moderate clinical history as a GHRH analog; outcome data is limited.
Long-term outcome data is limited; effects vary with age and baseline.
Both are GHRH analogs that prompt your own GH release rather than replacing it. Tesamorelin has the stronger pedigree, FDA-approved origins (Egrifta) and randomized trials behind the branded product, and is offered by request after clinician evaluation. Sermorelin is the everyday, 503A-eligible option available now. Compounded tesamorelin is not the approved product. The right route depends on goals, evaluation, and what's appropriate for you.
FDA-approved origins apply to the branded product, not compounded forms, compounded tesamorelin is not FDA-approved. Both are WADA-banned (S2) and clinician-gated; neither is a general weight-loss drug.
Tesamorelin has the stronger evidence pedigree thanks to its FDA-approved origins (Egrifta), but compounded forms aren't the approved product. Sermorelin is the everyday 503A-eligible GH-axis option available now. The right choice is a clinical decision.
Sermorelin is available now under a clinician (503A-eligible). Tesamorelin is by request after evaluation; an FDA-approved branded version exists, but compounded forms are not FDA-approved.